Diabetes update: Preventing type 2 diabetes. Individualized stepwise therapy (oral antidiabetic agents). Multifactorial intervention;Update diabetes mellitus typ 2: Primäre prävention, stufenschema der differenzialtherapie, kombinierte therapie

Praxis

Volumn 93, Issue 18, 2004, Pages 753-762

  Muller B ^a   Trepp, R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Diabetes mellitus type 2; Multifactorial intervention; Prevention; Stepwise therapy, oral antidiabetic agents; Treatment; Update

Indexed keywords

EID: 80051714860     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.93.18.753     Document Type: Review

References (42)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 21 1414-1431. (Pubitemid 28405191)
2. Birkeland KI, Berg JP. Type 2 diabetes - preventable, but how? Eur J Endocrinol 2001 145 573-575. (Pubitemid 33061901)
3. The Expert Committee on the Diagnosis and Classification of Diabetes mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997 20 1183-1197.
4. Jungste Version: The Expert Committee on the Diagnosis and Classification of Diabetes mellitus: Follow-up Report on the diagnosis of diabetes mellitus. Diabetes Care 2003 26 3160-3166.
5. Henkel E, Kohler C, Temelkova-Kurtschiev T, Hanfeld M. Pradiktoren von Glukosetoleranzstorungen in einer Risikopopulation fur Typ-2-Diabetes: die RIAD-Studie. Dtsch Med Wochenschr 2002 127 935-957.
6. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus chenage phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998 317 371-375.
7. Kohler C, Temelkova-Kurtschiev T, Schaper F, Fucker K, Hanefeld M. Pravalenz von neuentdecktem Diabetes, gestorter Glukosetoleranz und gestorter Nuchternglukose in einer Risikopopulation. Dsch Med Wochenschr 1999 124 1057-1061.
8. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999 22 562-568. (Pubitemid 29153041)
9. Pan XR, Li GW, Hu YH,Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY,Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997 20 537-544. (Pubitemid 27143412)
10. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 2001 1343-1350. (Pubitemid 32378388)
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 393-403. (Pubitemid 34437694)
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOPNIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 359 2072-7. (Pubitemid 34680970)
13. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 27 155-61. (Pubitemid 38196725)
14. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001 103: 357-62. (Pubitemid 32105973)
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 342 145-53.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-9. (Pubitemid 15018832)
17. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and the prevention of diabetes and related complications. Diabetes Care 2002 25 S1 50-60.
18. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999 16: 716-30
19. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 334 574-9. (Pubitemid 126537875)
20. Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001 109 Suppl 2 S 259-64.
21. R. Lehmann. Die Bedeutung der postprandialen Glykamie. Schweiz Rundsch Med Prax 2001 90 345-348.
22. Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980 3 58-62. (Pubitemid 10079157)
23. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 391577-83.
24. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000 23 349-53. (Pubitemid 30131743)
25. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003 25 327951-3.
26. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P,Waldenstrom A,Wedel H,Welin L Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995 26 57-65.
27. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997 24 314 1512-5.
28. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, Negut C, Palisi M, Bagolin E, Tiengo A. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002 51: 808-12. (Pubitemid 34760193)
29. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999 42 903-19. (Pubitemid 29369597)
30. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 30 348 383-93.
31. Sacks, FM, Tonkin, AM, Craven, T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424.31. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals. Lancet 2002; 360: 7.
32. Communique der Arbeitsgruppe Lipide und Atherosklerose der Schweizerischen Gesellschaft fur Kardiologie. G. Noseda,W. Riesen, R. Darioli, R. Mordasini. LDL-Cholesterin 2.6 mmol/l - neue Zielwert-Empfehlung der AGLA fur die Behandlung von Patienten mit hohem Risiko.
33. Gagne, C, Bays, HE,Weiss, SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002 90 1084.
34. Adler, AI, Stratton, IM, Neil, HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412.
35. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288: 2981.
36. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 355 253.
37. Lindholm, LH, Ibsen, H, Dahlof, B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 1004.
38. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002 26 106 2760-3.
39. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12; 352 (9131): 837-53.
40. American Diabetes Association. Position statement: Aspirin therapy in diabetes. Diabetes Care 2004 27 Suppl 1: S72-73.
41. Imoberdorf R. Jedem Diabetiker sein Aspirin. Schweiz Med Forum 2003 7 149-154.
42. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002 17 552-8. (Pubitemid 35265795)